An adjuvant is a substance formulated as part of a vaccine for enhancing its ability to induce protection against infection. Adjuvants are the substances, which are added to vaccines for enhancing the immunogenicity of highly purified antigens having insufficient immunostimulatory capabilities, and have been used, in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune-enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
The Global Vaccine Adjuvants Market is anticipated to grow at a CAGR of 12.5% and is expected to reach USD1328.4 million by 2026 from USD 517.74 million in 2018. The market is driven by factors like increase in government funding for research, expanding biotechnology and biopharmaceutical industries, the high prevalence of diseases, and a growing focus on the prevention of diseases. The rise in the occurrence of zoonotic and infectious syndromes, growing focus on the improved and emerging syndrome, and long-lasting vaccination are the other factors driving the market growth. The importance of adjuvant examination in vaccine expansion has increased due to the restricted immunogenicity of new and novel vaccine antigens. Few vaccines have novel adjuvant formulations, which are regularly reaching development stages and hence offering the latest equipment to fill former unmet clinical needs. On the other hand, several adjuvants fail at the time of product development owing to the aspects such as stability, lack of effectiveness, safety concerns, unacceptable levels of tolerability, or manufacturability.
Various governmental organizations are set to promote and raise awareness across the world, regarding immunization against various diseases, such as anthrax, BCG, hepatitis, influenza, varicella, smallpox, HPV, and other conditions. Thus, the increase in the risk of infectious diseases, enhanced immunogenicity, the effectiveness of vaccines, and various government initiatives will enhance the demand over the forecast period. The adjuvant market gains a boost from the increase in the use of recombinant subunit vaccines. With the increasing usage, the demand for various adjuvants is expanding. In the coming years, more developments are expected to occur, thereby increasing the need for adjuvants.
Vaccine adjuvants are in advancement stage, and currently, MF59 and aluminum salts are the only adjuvants that are feasible for human usage. Aluminum salts or aluminum gels are vaccine ingredients that have been using in vaccines since the 1930s. Small amounts of aluminum are added to the body for building stronger immunity against the germs in the vaccine. Aluminum is one of the common metals found in nature and is present in the air, water, and food. The amount of aluminum that is present in vaccines is low and is regulated by the U.S. Food and Drug Administration (FDA). MF59-adjuvanted influenza vaccine (FLUAD®) eliciting higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®) is a randomized, multicenter, Phase III pediatric trial. Pfizer Inc. announced that Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.S. Food and Drug Administration (FDA) approval for an expanded age indication to include adults 18 through 49 years of age in 2016.
Toxicity is the single-most crucial hinderance while introducing most of the adjuvants for use in humans. Toxicity may increase the financial burden on market players in the development and manufacturing phases. Hence, the negative effects of toxicity of adjuvants cost and safety profiles of vaccines in vaccine manufacturing are hindering the market growth. The high growth potential of emerging markets has opened an array of opportunities for market growth. However, the high cost of adjuvant-based research work and proven safety of adjuvants are hampering the growth of the global market.
The Global Vaccine Adjuvants Market is broadly segmented into Product Type, Route of Administration, Disease Type, Applications, Application categories, and Region.
By Product Type: Pathogen components, Adjuvant emulsions, Combination adjuvants, Particulate adjuvants, and Others. The particulate adjuvants segment is anticipated to account for the largest share of the global market in 2018. The adjuvant emulsions segment is expected to grow at the highest CAGR during the forecast period due to the rising prevalence of diseases such as allergy, cancer, and HIV/AIDS; development of improved vaccine immunization, and growing demand for advanced treatment options.
By Route of Administration: Oral, Subcutaneous, Intramuscular, Intradermal, Intranasal, and others. The intramuscular segment is projected to account for the largest share of the global vaccine adjuvants market in 2018. Factors including the rapidly growing geriatric population and vaccines for improved immunization are increasing the growth of the market. Rising collaborations and acquisitions by private organizations and increase in funding by government bodies for research and development are also projected to drive market growth.
By Disease type: Cancer, Infectious diseases, and Others. The infectious diseases segment is anticipated to account for the largest share of the global market in 2018 owing to the high prevalence of infectious diseases, government & company initiatives, and high prevalence of cancer cases that are going to drive market growth in the coming years.
By Application: Research and Commercial applications. The research applications segment is anticipated to account for the largest share of the market during the forecast period owing to ongoing research projects on new adjuvants, growing usage of many vaccine adjuvants commercially, increasing initiatives by government bodies and companies, and increasing incidences of zoonotic diseases.
By Application Categories: Human vaccine adjuvants and Veterinary vaccine adjuvants. The human vaccine adjuvants segment is projected to account for the largest share of the global market in 2018 and is also projected to grow at the higher CAGR owing to increasing initiatives by companies.
By Geographical Region: North America, Europe, Asia, and the Rest of the World (RoW). North America market dominates the global vaccine adjuvants market in terms of revenue contribution compared to other markets in other regions owing to the presence of well-developed healthcare infrastructure, skilled labors in the region. Europe accounts for second-largest revenue share contribution to the global vaccine adjuvants market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. Asia Pacific & Africa is expected to be the largest increasing global vaccine adjuvants market in the coming years due to the growing occurrence of HIV, hepatitis, influenza, cancer, and others.
The key players in the global vaccine adjuvants market include Agenus, Inc. (U.S.), Brenntag Biosector (Denmark), SEPPIC (France), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), CSL Limited (Australia), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), OZ Biosciences (France), MVP Laboratories, Inc. (U.S.), and others.
The report covers in-depth analysis of the Global Vaccine Adjuvants Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (cancer, melanoma, influenza, leukemia, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations
The report includes in-depth company profiles of key players in the Global Vaccine Adjuvants Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.